Proteostasis Therapeutics Announces Proposed Public Offering 9,000,000 Shares Of Common Stock

CAMBRIDGE, Mass., March 19, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent, or 1,350,000 shares, of the common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Proteostasis.

Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Proteostasis pursuant to a shelf registration statement (File No. 333-218545), which was declared effective by the Securities and Exchange Commission (SEC) on July 3, 2017. The offering will be made only by means of a preliminary prospectus supplement and accompanying prospectus. When available, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by email at and from RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.


Back to news